You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

What is severe asthma?

Asthma which requires the use of high dose inhaled corticosteroids (ICS) plus a second controller (and/or systemic corticosteroids) to prevent it from becoming ‘uncontrolled’ or which remains ‘uncontrolled’ despite this therapy. 1 (International European Respiratory Society [ERS] and American Thoracic Society [ATS] Task Force.)

REFRACTORY DISEASE

REFRACTORY DISEASE

Patients with refractory disease either remain uncontrolled despite their treatment being optimised or require high doses of controller and reliever medication to maintain control. 2

EOSINOPHILIC PHENOTYPE

EOSINOPHILIC PHENOTYPE

The eosinophilic asthma phenotype has been shown to be associated with asthma severity, late-onset disease and steroid refractoriness. 4

TARGETED THERAPIES

TARGETED THERAPIES

By characterising a patient’s severe asthma phenotype, they can be treated differently with personalised and targeted therapies, and outcomes could be improved. 4

Nucala is an anti-IL-5 treatment that specifically targets the eosinophilic phenotype. 5

Prevalence and burden

Prevalence and burden

Severe asthma patients are at high risk of having a severe exacerbation and are often dependent on oral corticosteroids. 4

These patients account for 50% of healthcare resource utilisation and have few therapeutic options available. 2,4

Nucala is an anti-IL-5 treatment that specifically targets the eosinophilic phenotype.

References:

  1. Chung KF, Wenzel SE, Brozek JL et al. Eur Respir J 2014;43:343–373.
  2. Peters S P, Ferguson G, Deniz Y et al. Respir med 2006;100:1139–1151.
  3. Walford H et al. E Journal Asthma Allergy 2014;11(7): 53-56
  4. Hoskins G, McCowan C, Neville RG. et al. Thorax 2000;55:19–24.
  5. Campo P, Rodriguez F, Sánchez-García et al. J Investig Allergol Clin Immunol 2013;23:76–88.
  6. Nucala Summary of Product Characteristics. Available from www.medicines.ie Last accessed: May 2020
  7. Walford H, Doherty T. J Asthma Allergy 2014;11:53–65.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting side effects you may get.

If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed on this website or in the product information leaflet. You can also report side effects directly to the HPRA Pharmacovigilance, Ireland.

Website: www.hpra.ie

By reporting side effects, you can help provide more information on the safety of this medicine.

Nucala is a registered trademark of the GlaxoSmithKline Group of Companies